Cowen Starts Immune Design (IMDZ) at Outperform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. META
7. CART
8. LLY
9. TSLA
10. FICO

Go back to Cowen Starts Immune Design (IMDZ) at Outperform

Immune Design Reports First Quarter 2015 Financial Results

May 14, 2015 6:00 AM EDT

SEATTLE and SOUTH SAN FRANCISCO, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results for the first quarter ended March 31, 2015.

First Quarter 2015 Highlights

In March 2015, Immune Design announced the dosing of patients in a Phase 1b clinical trial of CMB305. CMB305 is a novel immuno-oncology combination product candidate that involves the sequential dosing of two complementary agents, LV305 and G305, and is designed to synergistically induce anti-tumor cytotoxic T lymphocytes (CTLs) to target tumors... More